Zdrowie i gospodarka · 08/12/2021
FDA Releases Draft Guidance for IND Submissions of Individualized Antisense Oligonucleotide Drug Products
The FDA is releasing a draft guidance outlining its recommendations for chemistry, manufacturing, and controls information needed to support IND submissions for individualized antisense oligonucleotide drug products for severely debilitating or life-threatening diseases caused by unique genetic variants.